No Data
No Data
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
Craig-Hallum Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $21
New Analyst Forecast: $ACTU Given $21.0 Price Target
Craig-Hallum Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $21
Craig-Hallum Bullish on Actuate Therapeutics, Initiates With a Buy
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025